Loading...
OTCM
SWGHF
Market cap1.24bUSD
May 18, Last price  
27.00USD
Name

Sawai Group Holdings Co Ltd

Chart & performance

D1W1MN
OTCM:SWGHF chart
P/E
47.25
P/S
2.45
EPS
90.38
Vol. 1Y
—
Shs. 5Y
-2.57%
Rev. 5Y
1.50%
Div Yld LY
—
Div Yld TTM
—
Revenues
201.68b
+6.69%
34,316,877,99937,631,498,00044,284,395,00050,069,000,00063,853,000,00067,603,000,00080,502,000,00089,823,000,000105,454,000,000123,492,000,000132,428,000,000168,068,000,000184,341,000,000182,537,000,000187,219,000,000193,816,000,000200,344,000,000176,862,000,000189,024,000,000201,676,000,000
Net income
10.44b
-12.79%
2,259,701,0001,738,722,0002,438,841,0004,982,000,0007,183,000,0009,026,000,00012,022,000,00012,192,000,00014,053,000,00017,155,000,00015,914,000,00014,017,000,00019,376,000,00019,279,000,00012,340,000,000-28,269,000,00012,667,000,00013,695,000,00011,969,000,00010,438,000,000
CFO
7.43b
-73.31%
-4,370,177,0009,549,369,0003,168,756,0007,907,000,0005,938,000,0007,812,000,00012,256,000,00013,422,000,00012,112,000,00019,975,000,00023,270,000,00028,472,000,00042,924,000,00030,256,000,00031,857,000,00034,310,000,00013,026,000,00023,149,000,00027,851,000,0007,433,000,000
Dividend
Mar 30, 20270.17696 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sawai Group Holdings Co., Ltd., along with its subsidiaries, specializes in the research, development, manufacture, and commercialization of generic pharmaceuticals, primarily serving markets in Japan and the United States. The company's extensive portfolio encompasses a variety of generic medications, available in diverse dosage forms such as tablets, capsules, injectables, and liquid formulations (including syrups, ophthalmic, and nasal solutions). These address numerous therapeutic categories, including cardiovascular, gastro-intestinal, central nervous system, metabolic, anti-infective, anti-allergic, and anti-cancer treatments, in addition to vitamin preparations. Sawai distributes its generic products through a network that includes distributors, wholesalers, and retailers across Japan and the United States. Established in 1929, the firm maintains its headquarters in Osaka, Japan.

Key people

Taku Nakaoka
Senior Executive Officer, Group Chief Corporate Planning Officer, Group Chief Financial Officer, Group CCO, Group Chief Sustainability Officer, Director of Group Corporate Planning · since 2024
Mitsuo Sawai
Chairman of the Board, President, Group Chief Executive Officer, Group Chief Operating Officer, Chairman of Subsidiary, Representative Director · since 2023
Seiji Nishimura
Managing Executive Officer, Group Chief Marketing Officer · since 2024
Motohiko Kimura
Senior Managing Executive Officer, President of Subsidiary · since 2023
Shoji Yokota
Senior Managing Executive Officer, Group Chief Research & Development Officer, Director · since 2023
Toshiya Hasuo
Managing Executive Officer, Group Chief Production Officer, President of Subsidiary · since 2023
Nobuko Sugimoto
Managing Executive Officer, Group Chief Intellectual Property Officer · since 2023
Toru Terashima
Managing Executive Officer · since 2024
Toshiomi Nakate
Senior Executive Officer, Group Chief Quality & Safety Officer · since 2024
Toyohiro Sawada
Senior Executive Officer, Group Chief Product Strategy Officer, Director of Group of Product Strategy, Group Deputy Chief Research & Development Officer · since 2024
Ichiro Takahashi
Executive Officer, Director of Group General Affairs, Director of Brand Communication · since 2025
Koji Takeda
Executive Officer, Group Chief Digital Transformation Officer, Director of Group IT · since 2024
Yasuko Aitoko
Independent Director · since 2025
Independent Director · since 2023
Yukiyo Nose
Independent Director · since 2025
Independent Director · since 2021
Etsuko Taniguchi
Independent Director · since 2025
Nawomi Todo
Independent Director · since 2021
Tadao Tsubokura
Independent Director · since 2025
IPO date
Apr 01, 2021
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT